OncoMatch/Clinical Trials/NCT04136782
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
Is NCT04136782 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments including Albumin-bound paclitaxel combined with carboplatin and Epirubicin combined with docetaxel for breast cancer.
Treatment: Albumin-bound paclitaxel combined with carboplatin · Epirubicin combined with docetaxel — To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative (negative)
Required: ESR1 negative (negative)
Required: PR (PGR) negative (negative)
Disease stage
Required: Stage II, III
Excluded: Stage IV
Demographics
Prior therapy
Cannot have received: antineoplastic therapy
those who have received antineoplastic therapy
Cannot have received: neoadjuvant chemotherapy
Exception: patients who fail in 2 cycles of neoadjuvant chemotherapy and switch to other regimens or terminate chemotherapy
those who have received neoadjuvant chemotherapy but fail in 2 cycles of neoadjuvant chemotherapy and switch to other regimens or terminate chemotherapy
Lab requirements
Blood counts
normal routine blood test results
Kidney function
normal kidney function
Liver function
normal liver function
Cardiac function
near normal electrocardiographic manifestations
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04136782 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 negative is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR negative is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or III is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages